Physician profile
Eric A Schaff
NPI 1679548218
$540.36
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $240 · 2021: $167.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $81.27 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.63 | 2019-2021 | |
| Tris Pharma INC | $72.48 | 2020 | |
| Abbvie INC. | $56.48 | 2019-2021 | |
| Neurelis, INC. | $39.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $37.64 | 2019-2020 | |
| Cranial Technologies, INC | $25.37 | 2021 | |
| Mylan Pharmaceuticals INC. | $24.64 | 2020-2021 | |
| Ultragenyx Pharmaceutical INC. | $20.78 | 2020 | |
| Pfizer INC. | $16.31 | 2020 | |
| Neos Therapeutics, Lp | $16.31 | 2020 | |
| Mission Pharmacal Company | $16.01 | 2019 | |
| Genentech USA, INC. | $15.75 | 2020 | |
| Sobi, INC | $13.63 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.30 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $11.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Schaff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.